Binds Bacterium Or Component Thereof Or Substance Produced By Said Bacterium Patents (Class 424/150.1)
-
Patent number: 8067004Abstract: The invention provides a novel surface polypeptide from Neisseria meningitidis as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Pharmaceutical compositions containing the polypeptide and nucleic acids of the invention are also disclosed as well as methods useful in the treatment, prevention and diagnosis of N. meningitidis infection.Type: GrantFiled: August 11, 2003Date of Patent: November 29, 2011Assignee: The University of QueenslandInventors: Ian Richard Anseim Peak, Michael Paul Jennings, E. Richard Moxon
-
Publication number: 20110274700Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: ApplicationFiled: May 9, 2011Publication date: November 10, 2011Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Publication number: 20110250202Abstract: The present invention provides PBP2a peptide antigens for generating antibodies against MRSA, and provides high-affinity binding agents that detect MRSA by selective immunoreactivity with PBP2a. The antibodies are useful in methods and systems for detecting MRSA, including biosensor systems, or as components of diagnostic or detection kits. The antibodies, in some embodiments, have therapeutic value against MRSA infection.Type: ApplicationFiled: May 7, 2009Publication date: October 13, 2011Applicant: Innovative Biosensors, Inc.Inventors: Colette Cote, Qiao-Xi Zheng, Venkatakrishna Shyamala, Tom Hazel
-
Patent number: 8030471Abstract: The subject invention relates to nucleic acid sequences and amino acid sequences encoded thereby, derived from the Merozoite Surface Protein (MSP1) gene of the Plasmodium species P. malariae and P. ovale. Such genes and proteins have many beneficial diagnostic as well as therapeutic uses.Type: GrantFiled: June 20, 2008Date of Patent: October 4, 2011Assignee: Abbott LaboratoriesInventors: Larry G. Birkenmeyer, Anthony S. Muerhoff, Suresh M. Desai, George J. Dawson, Bruce J. Dille
-
Publication number: 20110236306Abstract: This invention provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individual's immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system.Type: ApplicationFiled: March 28, 2011Publication date: September 29, 2011Inventors: STEVEN D. GOODMAN, LAUREN O. BAKALETZ
-
Publication number: 20110236393Abstract: The presently disclosed subject matter provides methods of inhibiting a host innate response to activator-mediated proliferative signals in a primary B cell. In some embodiments a method is provided for immortalized primary B cells. In some embodiments a method is provided for increasing efficiency of EBV transformation of primary B cells. In some embodiments a method is provided for increasing proliferation of primary B cells in culture. In some embodiments a method is provided for producing a monoclonal antibody. In some embodiments a method is provided for identifying a novel broadly neutralizing antibody having a desired antigen specificity. Also provided are antibodies produced according the methods of the presently disclosed subject matter.Type: ApplicationFiled: November 4, 2009Publication date: September 29, 2011Inventors: Kwan-ki Hwang, Micah Luftig
-
Patent number: 8021645Abstract: A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and pentameric IgM with secretory component to form a antigen specific dimeric secretory IgA and pentameric secretory IgM therapeutic. The antigen specific dimeric secretory IgA and the pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, liquid or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.Type: GrantFiled: June 13, 2008Date of Patent: September 20, 2011Inventors: Michael R. Simon, Stephanie M. Chervin, Stephen C. Brown
-
Patent number: 7985410Abstract: The purpose of the present invention is to provide a method and an agent to efficiently inhibit the function of the drug efflux pump of Pseudomonas aeruginosa. The invention provides a method to inhibit the function of the drug efflux pump of Pseudomonas aeruginosa, comprising modifying any amino acid residue selected from 100th to 109th or 311th to 320th amino acid residues in the amino acid sequence of mature OprM protein. The invention also provides an agent having such inhibitory effect, and a screening method thereof.Type: GrantFiled: February 9, 2007Date of Patent: July 26, 2011Assignee: Tokai UniversityInventors: Eisaku Yoshihara, Hidatoshi Inoko
-
Publication number: 20110150896Abstract: Provided is an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Provided are a monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient. Concretely, monoclonal antibody of the present invention has excellent inhibiting activity on cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the monoclonal antibody of the present invention has high affinity with PcrV.Type: ApplicationFiled: January 8, 2009Publication date: June 23, 2011Applicant: Shionogi & Co., Ltd.Inventors: Yoshito Numata, Yoshinori Yamano, Takafumi Sato, Toshinaga Tsuji
-
Publication number: 20110129460Abstract: The invention relates to methods and compositions for the prevention and treatment of disease caused by B. anthracis or a bacterium which produces toxins or toxin components homologous to the virulence factors produced by B. anthracis or to the toxins or toxin components themselves, in the absence of bacteria. The methods and compositions of the invention comprise a combination of at least two antibodies, preferably monoclonal antibodies, most preferably human monoclonal antibodies, each of which binds with high affinity to a different epitope of one or more bacterial antigens.Type: ApplicationFiled: July 21, 2010Publication date: June 2, 2011Applicant: IQ Therapeutics B.V.Inventor: Herman Groen
-
Publication number: 20110117104Abstract: Disclosed is a monoclonal antibody having very high affinity to anthrax toxin and potent toxin-neutralizing activity. Also disclosed are a composition for neutralizing anthrax toxin comprising the antibody and a kit for detecting anthrax toxin.Type: ApplicationFiled: March 10, 2006Publication date: May 19, 2011Applicant: Aprogen Inc.Inventors: Hyo Jeong Hong, Kyung Soo Inn, Nam Kyu Lim, Jung Whan Kim, Keun Soo Kim, Sang Yoon Lee, Se Yeon Kim, Hyun Jung Kang, Mee Sook Oh
-
Publication number: 20110110954Abstract: Compositions and methods effective for eliciting an immune response for preventing or reducing infection or improving clinical outcomes caused by Bacillus anthracis are provided. The compositions include a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of an antigenic epitope associated with anthrax toxin proteins optionally combined with a pharmaceutically acceptable carrier. The preferred antigenic epitopes correspond to immunogenic regions of protective antigen, lethal factor or edema factor, either individually or in combination. In addition, methods and compositions containing antibodies for reducing the effects of anthrax toxins are described. The methods involve administering to a human or animal the compositions described herein in a dosage sufficient to elicit an immune response or treat the anthrax infection.Type: ApplicationFiled: September 13, 2010Publication date: May 12, 2011Applicant: Oklahoma Medical Research FoundationInventors: Judith A. James, Darise Farris, Sherry Crowe
-
Patent number: 7914791Abstract: A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.Type: GrantFiled: May 10, 1999Date of Patent: March 29, 2011Assignee: Trident Pharmaceuticals, Inc.Inventors: Timothy Raymond Hirst, Neil Andrew Williams, Andrew Morgan, Andrew Douglas Wilson, Lucy Amber Bird
-
Patent number: 7910096Abstract: Human and humanized monoclonal antibodies which binds specifically to subunit A of Shiga like toxin II have been developed which are effective to prevent or ameliorate one or more symptoms of HUS in a human. Effective dosages for treatment or prevention range from approximately 0.1 to 5.0 mg of antibody/kg of patient weight. The examples demonstrate the preferred dosage ranges based on the pig model, and what is being tested in phase I clinical trials. Antibodies are preferably transfused over a period of two hours, although this will depend on the patient and the disease state at the time of treatment. Preferred dosages for treatment of humans are between 0.1 mg/kg-5.0 mg/kg of 5C120, or an equivalent dosage of another antibody to subunit A of STX2. In the most preferred embodiments, dosages of 0.1 mg/kg, 0.5 mg/kg, or 5.0 mg/kg of 5C12 (low dose, anticipated therapeutic dose based on animal data and high dose) are administered.Type: GrantFiled: October 31, 2007Date of Patent: March 22, 2011Assignee: Trustees of Tufts CollegeInventors: Saul Tzipori, Ramaswamy Balakrishnan, Arthur Donohue-Rolfe
-
Patent number: 7910095Abstract: Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome by administration of the monoclonals to the individual in need of treatment or protection.Type: GrantFiled: August 24, 2007Date of Patent: March 22, 2011Assignee: Trustees of Tufts CollegeInventors: Saul Tzipori, Ramaswamy Balakrishnan, Arthur Donohue-Rolfe
-
Patent number: 7906277Abstract: Compounds and methods for diagnosing tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of one or more M. tuberculosis proteins, and DNA sequences encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of M. tuberculosis infection in patients and biological samples. Antibodies directed against such polypeptides are also provided.Type: GrantFiled: August 16, 2006Date of Patent: March 15, 2011Assignee: Corixa CorporationInventors: Steven R. Reed, Yasir A. W. Skeiky, Davin C. Dillon, Antonio Campos-Neto, Raymond Houghton, Thomas S. Vedvick, Daniel R. Twardzik, Michael J. Lodes, Ronald C. Hendrickson
-
Patent number: 7906119Abstract: The present invention relates to antibodies and related molecules that specifically bind to protective antigen of Bacillus anthracis (PA). Such antibodies have uses, for example, in the prevention and treatment of anthrax and anthrax toxin poisoning. The invention also relates to nucleic acid molecules encoding anti-PA antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.Type: GrantFiled: April 9, 2009Date of Patent: March 15, 2011Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Michael W. Laird, Reiner L. Gentz
-
Publication number: 20110059086Abstract: Disclosed are EspFU (EspF-like polypeptide encoded by a gene of the cryptic prophage CP-933U of enterohemorrhagic E. coli) polypeptides, fragments thereof, nucleic acids that encode EspFU polypeptides, or fragments thereof, and cells including the polypeptides, fragments, and/or nucleic acids. Also disclosed are model systems, kits, and methods for screening that use, for example, EspFU polypeptides and nucleic acids. Also included are pharmaceutical and diagnostic compositions and methods of diagnosis and treatment of EHEC infections.Type: ApplicationFiled: June 7, 2010Publication date: March 10, 2011Applicant: UNIVERSITY OF MASSACHUSETTSInventors: John M. Leong, Kenneth G. Campellone
-
Patent number: 7901687Abstract: The present invention relates to conjugates of oligosaccharides of formula 1, wherein R is a linker to a carrier protein and optionally comprises up to three further saccharides, 5 and which are useful for vaccination, methods of synthesis of such conjugates, antibodies against this antigen, hybridoma producing monoclonal antibodies against this antigen, assays using these antibodies for the detection of B. anthracis spores and kits comprising these antibodies, and a vaccine for the prevention of B. anthracis infection comprising the conjugates of oligosaccharides of formula 1. Monoclonal antibodies 10 according to the invention selectively bind to B. anthracis, but not to related bacteria such as B. subtilis, B. cereus and other bacteria of this group such as B. thuringiensis.Type: GrantFiled: April 27, 2007Date of Patent: March 8, 2011Assignees: Eth Zurich, Schweizerisches TropeninstitutInventors: Daniel B. Werz, Peter H. Seeberger, Marco Tamborrini, Gerd Pluschke
-
Patent number: 7884198Abstract: The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.Type: GrantFiled: December 23, 2008Date of Patent: February 8, 2011Assignees: The Henry M. Jackon Foundation for the Advancement of Military Medicine, Altor Bioscience CorporationInventors: Gerald Walter Fischer, Richard F. Schuman, Hing Wong, Jeffrey R. Stinson
-
Publication number: 20110027280Abstract: The present invention relates to methods for the killing of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. This has the effect of inducing rapid cell death (autolysis) in the majority of bacterial cells, and preventing virulence or restoring a benign state in surviving cells. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease management, and in related applications where the host for infection is an animal or plant. The compositions described herein are particularly relevant to Pseudomonas aeruginosa infection, for example in the treatment of pulmonary infection in cystic fibrosis patients, and represent a unique bactericidal medication that does not directly target the bacteria.Type: ApplicationFiled: July 16, 2010Publication date: February 3, 2011Applicant: HAPTOGEN LTD.Inventors: Keith Alan Charlton, Andrew Justin Radcliffe Porter, Ian Broadbent
-
Publication number: 20110027265Abstract: Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing HIa to provide immunoprotection against S. aureus pneumonia. In certain aspects the invention includes a HIa with reduced toxicity, represented by a recombinant mutant form of HIa (HlaH35L) in which histidine 35 is converted to leucine, which can be used to abrogate the productive assembly of the toxin and protect a subject from staphylococcal pneumonia.Type: ApplicationFiled: August 29, 2008Publication date: February 3, 2011Applicant: The University of ChicagoInventors: Juliane Bubeck-Wardenburg, Olaf Schneewind, Brook Ragle
-
Publication number: 20110002937Abstract: This invention relates to a novel hybridoma strategy that uses CD27+ B cells cultured in vitro to induce IgM to IgG class switch prior to fusion with a fusion partner. Hybridomas resulting from the fusion between CD27+ B cells and a fusion partner cell line and antibodies secreted from the hybridomas are included in the invention.Type: ApplicationFiled: January 28, 2009Publication date: January 6, 2011Applicant: THOMAS JEFFERSON UNIVERSITYInventors: Scott K. Dessain, Sharad P. Adekar
-
Publication number: 20100322944Abstract: A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody can be a monoclonal antibody having both an antigen-binding portion that binds at least one bacterial antigen and a constant region that does not bind staphylococcal protein A.Type: ApplicationFiled: August 31, 2010Publication date: December 23, 2010Applicant: STROX BIOPHARMACEUTICALS, LLCInventor: Stanley Arthur Kim
-
Patent number: 7851170Abstract: Hybridoma cell lines which produce and secrete monoclonal antibodies which selectively bind to Mycobacterium avium subspecies paratuberculosis have been produced. Cells of M. avium subspecies paratuberculosis in biological samples may be detected and quantified by contacting the sample with the antibodies to form a M. avium subspecies paratuberculosis/antibody immunocomplex when M. avium subspecies paratuberculosis is present, which immunocomplex may then be detected. The monoclonal antibodies also may be incorporated into kits for the detection and quantification of M. avium subspecies paratuberculosis.Type: GrantFiled: December 17, 2008Date of Patent: December 14, 2010Assignee: The United States of America as represented by the Secretary of AgricultureInventor: John P. Bannantine
-
Patent number: 7846435Abstract: The invention provides humanized antibodies that specifically bind to, and preferably, neutralize, verotoxin II (VT2). The antibodies are useful for treating patients suffering from, or at risk of suffering, toxic effects of verotoxin.Type: GrantFiled: May 19, 1999Date of Patent: December 7, 2010Assignees: Teijin Limited, PDL Biopharma, Inc.Inventors: Yoh-Ichi Matsumoto, Atsuchi Imaizumi, Tsuyoshi Kimura, Tae Takeda, Yoshifumi Takeda, legal representative, Man Sung Co, Maximiliano Vasquez
-
Publication number: 20100297133Abstract: Provided herein are compositions and methods for eliciting an immune response against Streptococcus pneumoniae. More particularly, the compositions and methods relate to immunogenic polypeptides, including fragments of PhtD and variants thereof, and nucleic acids, vectors and transfected cells that encode or express the polypeptides. Methods of making and using the immunogenic polypeptides are also described.Type: ApplicationFiled: July 23, 2008Publication date: November 25, 2010Inventors: Martina Ochs, Roger Brookes, Robert Charlebois, Jeremy Yethon
-
Publication number: 20100291100Abstract: The present invention provides genes encoding novel microbial proteins (i.e., for example, exosporium genes and proteins) that mediate the attachment of microbial spores to surfaces. Specific fragments of these microbial spore proteins may be utilized to inhibit the attachment of microbial spores to surfaces, thereby providing an infection control agent. The invention provides recombinant expression vectors comprising genes encoding exosporium proteins, as well as host cells containing these expression vectors. Further provided herein are screening methods for identifying infection control compositions comprising exosporium proteins that inhibit bacterial spore attachment to either bodily tissues or solid surfaces. Additionally, the invention provides for the use of nucleic acid inhibitors of exosporium protein expression by hybridizing with nucleic acid sequences encoding exosporium proteins as well as with exosporium mRNA.Type: ApplicationFiled: March 26, 2010Publication date: November 18, 2010Inventor: David R. Macinga
-
Patent number: 7825225Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: July 24, 2009Date of Patent: November 2, 2010Assignee: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Publication number: 20100260752Abstract: This invention provides binding molecules with improved binding affinity to lipoteichoic acids exposed on the surface of the bacteria, useful in the prevention and treatment of infections caused by Gram positive bacteria.Type: ApplicationFiled: January 22, 2010Publication date: October 14, 2010Applicant: Biosynexus IncorporatedInventor: Ying TANG
-
Patent number: 7807139Abstract: The present invention provides a method for the treatment and/or prevention of bacterial infection caused by Klebsiella pneumoniae and other gram-negative bacteria in central nervous system and/or peripheral blood circulation in a mammal by administering effective amount of outer membrane protein A (OmpA) or its derivatives to a mammal. Also provided are a method for vaccinating a mammal to produce an antibody against bacterial infection caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation and a method of detecting or diagnosing bacterial infections caused by Enterobacteriaceae family in central nervous system and/or peripheral blood circulation in a mammal.Type: GrantFiled: January 23, 2009Date of Patent: October 5, 2010Assignee: Taipei Medical UniversityInventors: Yi-Yuan Yang, Hsueh-Hsia Wu, Sy-Jye Leu, Neng-Yao Shih, I-Jen Huang, Ching-Yu Lin, Wen-Shyang Hsieh, Ko-Jiunn Liu, Shih-Yi Huang, Yueh-Lun Lee, Chi-Hsin Lee, Yuan-Soon Ho, Shih-Lan Hsu
-
Publication number: 20100247546Abstract: The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.Type: ApplicationFiled: October 2, 2009Publication date: September 30, 2010Applicants: HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, ALTOR BIOSCIENCE CORPORATIONInventors: GERALD WALTER FISCHER, RICHARD F. SCHUMAN, HING WONG, JEFFREY R. STINSON
-
Publication number: 20100239583Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating infections and diseases using anti-flagellin antibodies in humans, other animals and birds.Type: ApplicationFiled: March 4, 2010Publication date: September 23, 2010Applicant: INOTEK PHARMACEUTICALS CORPORATIONInventors: Kanneganti MURTHY, Andrew L. SALZMAN
-
Publication number: 20100233181Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.Type: ApplicationFiled: July 31, 2009Publication date: September 16, 2010Applicants: UNIVERSITY OF MASSACHUSETTS, MEDAREX, INC.Inventors: Donna AMBROSINO, Gregory J. BABCOCK, Teresa BROERING, Robert GRAZIANO, Hector Javier HERNANDEZ, Israel LOWY, Robert MANDELL, Deborah MOLRINE, William D. THOMAS, JR., Hui-Fen ZHANG
-
Publication number: 20100233182Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.Type: ApplicationFiled: July 31, 2009Publication date: September 16, 2010Applicants: UNIVERSITY OF MASSACHUSETTS, MEDAREX, INC.Inventors: Donna AMBROSINO, Gregory J. BABCOCK, Teresa BROERING, Robert GRAZIANO, Hector Javier HERNANDEZ, Israel LOWY, Robert MANDELL, Deborah MOLRINE, William D. THOMAS, JR., Hui-Fen ZHANG
-
Patent number: 7794721Abstract: A composition for treating a subject is provided. The composition includes a pentameric secretory IgM therapeutic. Formulating agents are mixed with the pentameric secretory IgM to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of pentameric IgM with secretory component to form a pentameric secretory IgM therapeutic. The pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.Type: GrantFiled: September 7, 2007Date of Patent: September 14, 2010Inventor: Michael R. Simon
-
Patent number: 7785571Abstract: A composition comprising an antibody or an antigen binding fragment thereof specific for at least one epitope of hsp90 from an organism of the Aspergillus genus, and at least one antifungal agent selected from the group consisting of: itraconazole and voriconazole.Type: GrantFiled: April 18, 2005Date of Patent: August 31, 2010Assignee: Neutec Pharma LimitedInventors: James Peter Burnie, Ruth Christine Matthews
-
Patent number: 7777017Abstract: The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.Type: GrantFiled: March 13, 2007Date of Patent: August 17, 2010Assignee: Biosynexus IncorporatedInventors: Jeffrey R. Stinson, Richard F. Schuman, James Jacob Mond, Andrew Lees, Gerald Walter Fischer
-
Publication number: 20100196391Abstract: The present invention relates to compositions and methods for blocking entry of Shigella into a cell of an animal, to therefore providing protection against, or reduce the severity of Shigella infections. More particularly it relates to the use of the IpaD protein obtained from natural sources and/or through synthesis or recombinant technology, and conjugates thereof to induce neutralizing antibodies having protective activity against several serotypes of Shigella, in particular S. flexneri. The composition of the invention is useful to prevent and/or treat shigellosis caused by a bacterium of the Shigella family.Type: ApplicationFiled: October 12, 2007Publication date: August 5, 2010Inventors: Adbelmounaaïm Allaoui, Philippe Sansonetti, Musa Sani, Anne Botteaux, Claude Parsot
-
Publication number: 20100183623Abstract: Monoclonal antibodies which can bind to the SdrF protein of Staphylococcus epidermidis are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus epidermidis. The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of the S. epidermidis SdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.Type: ApplicationFiled: June 16, 2006Publication date: July 22, 2010Inventors: Joseph M. Patti, Jeff T. Hutchins, Andrea Hall, Linda Santos, Maria Bowden, Magnus Hook
-
Patent number: 7759462Abstract: A polypeptide, called Tir (for translocated intimin receptor, which is secreted by attaching and effacing pathogens, such as the enteropathogenic (EPEC) and enterohemorrhagic (EHEC) E. coli. These bacterial pathogens inserts their own receptors into mammalian cell surfaces, to which the bacterial pathogen then adheres to trigger additional host signaling events and actin nucleation. Diagnosis of disease caused by pathogenic E. coli can be performed by the use of antibodies which bind to Tir to detect the protein or the use of nucleic acid probes for detection of nucleic acids encoding Tir polypeptide. Isolated nucleic acid sequences encoding Tir polypeptide, Tir peptides, a recombinant method for producing recombinant Tir, antibodies which bind to Tir, and a kit for the detection of Tir-producing E. coli are provided. A method of immunizing a host with Tir to induce a protective immune response to Tir or a second polypeptide of interst is also provided.Type: GrantFiled: November 9, 2006Date of Patent: July 20, 2010Assignee: University of British ColumbiaInventors: Brett B. Finlay, Brendan Kenny, Rebekah DeVinney, Markus Stein
-
Patent number: 7749499Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 30, 2007Date of Patent: July 6, 2010Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20100166732Abstract: The present invention relates to a peptide consisting of one antigen of Streptococcus pyogenes (S. pyogenes) of any of the SEQ ID NOS: 1 to 7 or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition, especially a vaccine, comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing a S.Type: ApplicationFiled: July 6, 2007Publication date: July 1, 2010Applicant: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Alexander von Gabain, Manfred Berger, Beatrice Senn, Michael Schunn
-
Publication number: 20100150934Abstract: This invention provides botulinum antitoxin compositions and methods of production, and methods of treating animals and humans prophylactically and also those suspected of having contacted botulism toxin. The botulinum antitoxin is prepared by inoculating an animal with a monovalent botulinum toxoid and toxin. The animal's plasma is collected and purified at a high pH by affinity chromatography. The resulting monovalent immunoglobulins are de-speciated by digestion with pepsin. Monovalent antitoxins for all seven botulinum serotypes are then combined to produce a high titered heptavalent botulinum antitoxin composition.Type: ApplicationFiled: December 11, 2009Publication date: June 17, 2010Inventors: Nicholas Pomato, Martin V. Haspel, Janet H. Ransom
-
Patent number: 7727711Abstract: Disclosed are antibodies that bind to the antigenic proteins GroES, RpIL, GroEL, SodB, UbiG, the ABC transporter, and an expressed antigenic protein of unknown function (the “BepA” protein) of Bartonella henselae, and use of these antigenic proteins in immunoassays in order to determine whether a sample from a subject contains one or more of these antibodies. Presence of such an antibody in the subject indicates that the subject is or was infected with Bartonella henselae, or indicates that the subject has an increased likelihood of being infected presently or in the past with Bartonella henselae. Also disclosed are kits for performing immunoassays, wherein each kit contains one or more of these antigenic proteins and also contains the reagents necessary for conducting an immunoassay.Type: GrantFiled: March 7, 2008Date of Patent: June 1, 2010Assignee: Medical Diagnostic Laboratories, LLCInventors: Tera L. McCool, Chien Chang Loa, Eli Mordechai, Martin E. Adelson
-
Patent number: 7718779Abstract: In this application are described monoclonal antibodies which specifically recognize V antigen of Y. pestis and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of plague infections in vitro and in vivo.Type: GrantFiled: November 12, 2004Date of Patent: May 18, 2010Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Tran C. Chanh, Gerard P. Andrews, Jeffrey J. Adamovicz, Bradford S. Powell
-
Patent number: 7713527Abstract: Piglet feed is supplemented with anti-E. coli K88 antibody-containing egg powder having a titer of the K88 antibodies of at least 1/256,000 as a means of improving growth performance of piglets.Type: GrantFiled: September 18, 2006Date of Patent: May 11, 2010Inventors: Maiti Pradip, John Hare
-
Publication number: 20100111868Abstract: Isolated monoclonal antibodies that bind and/or neutralize anthrax protective antigen (PA) are disclosed as well as hybridomas secreting such antibodies. The invention also provides anti-PA fragments of the antibodies of the invention and recombinantly produced antibodies. Also provided are pharmaceutical compositions containing the antibodies or antibody fragments and uses and methods involving same.Type: ApplicationFiled: September 3, 2009Publication date: May 6, 2010Inventor: Wei-Gang HU
-
Publication number: 20100080805Abstract: A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed.Type: ApplicationFiled: November 17, 2009Publication date: April 1, 2010Applicant: Technion Research & DevelopmentInventors: Yoram Reiter, Cyril Cohen
-
Patent number: 7687278Abstract: A pretreatment kit and a pretreatment kit for saliva in identification and quantitative determination of Streptococci mutans by immunochromatography utilizing an antigen-antibody reaction, which can remove aggregation caused by mucin and chain formation of Streptococci mutans in saliva in a simple operation and can efficiently flow out a complex of a labeled antibody and Streptococci mutans from a porous membrane retaining the labeled antibody, contains (A) a 0.01 to 10 mol/L aqueous solution of sodium hydroxide, (B) a 0.01 to 3 mol/L aqueous solution of tartaric acid and/or citric acid, and (C) a nonionic surface active agent and/or an amphoteric surface active agent, in which the component (C) is mixed with the components (A) and/or (B), or is provided separately, and at least one substance selected from the particular metallic salts is contained in at least one of the components (A), (B) and (C) in an amount of 5 to 25% by weight.Type: GrantFiled: April 13, 2006Date of Patent: March 30, 2010Assignee: GC CorporationInventor: Atsushi Tachino